In silico screening, pharmacokinetic, DFT, and dynamics simulation study of ant-hepatitis C virus compounds as potential NS5B Polymerase inhibitors
Cirrhosis, hepatocellular carcinoma, and other serious liver diseases are caused by the hepatitis C virus (HCV) infection. An oral NS5B inhibitor for the therapy of HCV called Sofosbuvir has received approval. However, its high cost and numerous side effects are emphasized. Therefore, alternative HC...
Main Authors: | Stephen Ejeh, Adamu Uzairu, Gideon Adamu Shallangwa, Stephen Eyije Abechi, Muhammad Tukur Ibrahim |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2024-03-01
|
Series: | Scientific African |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2468227624000474 |
Similar Items
-
In silico design and pharmacokinetics investigation of some novel hepatitis C virus NS5B inhibitors: pharmacoinformatics approach
by: Stephen Ejeh, et al.
Published: (2022-04-01) -
Computational insight to design new potential hepatitis C virus NS5B polymerase inhibitors with drug-likeness and pharmacokinetic ADMET parameters predictions
by: Stephen Ejeh, et al.
Published: (2021-10-01) -
Computer-aided identification of a series of novel ligands showing high potency as hepatitis C virus NS3/4A protease inhibitors
by: Stephen Ejeh, et al.
Published: (2021-01-01) -
Chemical bioinformatics study of Nonadec-7-ene-4-carboxylic acid derivatives via molecular docking, and molecular dynamic simulations to identify novel lead inhibitors of hepatitis c virus NS3/4a protease
by: Stephen Ejeh, et al.
Published: (2023-07-01) -
Computational and pharmacokinetics studies of 1,3-dimethylbenzimidazolinone analogues of new proposed agent against Alzheimer's disease
by: Abduljelil Ajala, et al.
Published: (2022-04-01)